Article Figures & Data
Tables
Bio-demographic data n (%) Age in years 18-25 1212 (47.9) 26-35 703 (27.8) 36-50 497 (19.6) 51-60 87 (3.4) >60 31 (1.2) Gender Male 1037 (41.0) Female 1493 (59.0) Educational level Primary or less 26 (1.0) Intermediate / secondary 567 (22.4) University 1937 (76.6) Work Healthcare workers 677 (26.8) Others 1853 (73.2) Body mass index Underweight 170 (6.7) Normal 1224 (48.4) Overweight 680 (26.9) Obese 279 (11.0) Morbid obesity 177 (7.0) Smoking Yes 412 (16.3) No 2118 (83.7) Chronic health problems Yes 372 (14.7) No 2158 (85.3) Had any type of allergy Yes 366 (14.5) No 2164 (85.5) COVID-19 infection and vaccination data n (%) Previously had positive test for COVID-19 Yes 488 (19.3) No 2042 (80.7) Type of vaccine Pfizer 1868 (73.8) AstraZeneca 662 (26.2) Agree to have second dose of COVID-19 vaccine Yes 1575 (62.3) No 435 (17.2) Had both doses 520 (20.6) Infected with COVID-19 after vaccination After 1st dose 132 (5.2) After 2nd dose 18 (0.7) No 2380 (94.1) Post-vaccination side-effects Yes 2213 (87.5) No 317 (12.5) - Table 3
- Distribution of post vaccination side effects among study population by vaccine type, Saudi Arabia.
Type of vaccine Side effects None After 1st dose After 2nd dose After both doses n (%) n (%) n (%) n (%) Pfizer Systemic side effects Headache 1108 (59.3) 648 (34.7) 60 (3.2) 52 (2.8) Fatigue 1433 (76.7) 352 (18.8) 57 (3.1) 26 (1.4) Fever 1367 (73.2) 360 (19.3) 106 (5.7) 35 (1.9) Chills and tremors 1635 (87.5) 177 (9.5) 41 (2.2) 15 (0.8) Joint pain 1456 (77.9) 326 (17.5) 51 (2.7) 35 (1.9) Muscle pain 1142 (61.1) 592 (31.7) 70 (3.7) 64 (3.4) Diarrhea 1742 (93.3) 103 (5.5) 21 (1.1) 2 (0.1) Nausea 1676 (89.7) 154 (8.2) 27 (1.4) 11 (0.6) Local SE Local pain 888 (47.5) 826 (44.2) 45 (2.4) 109 (5.8) Local edema 1428 (76.4) 365 (19.5) 32 (1.7) 43 (2.3) Local pain with touch 560 (30.0) 1091 (58.4) 56 (3.0) 161 (8.6) Itching 1652 (88.4) 185 (9.9) 20 (1.1) 11 (0.6) Axiliary lymphadenopathy 1790 (95.8) 56 (3.0) 18 (1.0) 4 (0.2) Local redness 1561 (83.6) 255 (13.7) 27 (1.4) 25 (1.3) Local bruising 1714 (91.8) 128 (6.9) 16 (0.9) 10 (0.5) Local hotness 1378 (73.8) 409 (21.9) 31 (1.7) 50 (2.7) AstraZeneca Systemic side effects Headache 272 (41.1) 370 (55.9) 8 (1.2) 12 (1.8) Fatigue 367 (55.4) 267 (40.3) 9 (1.4) 19 (2.9) Fever 218 (32.9) 414 (62.5) 7 (1.1) 23 (3.5) Chills and tremors 386 (58.3) 257 (38.8) 6 (0.9) 13 (2.0) Joint pain 394 (59.5) 246 (37.2) 11 (1.7) 11 (1.7) Muscle pain 312 (47.1) 328 (49.5) 10 (1.5) 12 (1.8) Diarrhea 582 (87.9) 70 (10.6) 7 (1.1) 3 (0.5) Nausea 513 (77.5) 142 (21.5) 3 (0.5) 4 (0.6) Local SE Local pain 284 (42.9) 343 (51.8) 5 (0.8) 30 (4.5) Local edema 491 (74.2) 158 (23.9) 6 (0.9) 7 (1.1) Local pain with touch 166 (25.1) 452 (68.3) 8 (1.2) 36 (5.4) Itching 568 (85.8) 87 (13.1) 4 (0.6) 3 (0.5) Axillary lymphadenopathy 629 (95.0) 28 (4.2) 3 (0.5) 2 (0.3) Local redness 551 (83.2) 100 (15.1) 4 (0.6) 7 (1.1) Local bruising 585 (88.4) 67 (10.1) 5 (0.8) 5 (0.8) Local hotness 466 (70.4) 179 (27.0) 3 (0.5) 14 (2.1) - Table 4
- Determinants of developing post-vaccination side-effects among study participants.
Factors Yes No P-value n (%) n (%) Age in years 18-25 1081 (89.2) 131 (10.8) 0.017* 26-35 615 (87.5) 88 (12.5) 36-50 413 (83.1) 84 (16.9) 51-60 77 (88.5) 10 (11.5) >60 27 (87.1) 4 (12.9) Gender Male 897 (86.5) 140 (13.5) 0.219 Female 1316 (88.1) 177 (11.9) Nationality Saudi 2097 (87.2) 309 (12.8) 0.036* Non-Saudi 116 (93.5) 8 (6.5) Body mass index Non obese 1211 (86.9) 183 (13.1) 0.314 Overweight / obese 1002 (88.2) 134 (11.8) Educational level Below university 456 (76.9) 137 (23.1) 0.001* University 1757 (90.7) 180 (9.3) Work HCWs 606 (89.5) 71 (10.5) .061 Others 1607 (86.7) 246 (13.3) Smoking Yes 384 (93.2) 28 (6.8) 0.001* No 1829 (86.4) 289 (13.6) Chronic health problems Yes 332 (89.2) 40 (10.8) 0.262 No 1881 (87.2) 277 (12.8) Had any type of allergy Yes 325 (88.8) 41 (11.2) 0.407 No 1888 (87.2) 276 (12.8) Previously had positive test for COVID-19 Yes 401 (82.2) 87 (17.8) 0.001* No 1812 (88.7) 230 (11.3) Type of vaccine Pfizer 1589 (85.1) 279 (14.9) 0.001* AstraZeneca 624 (94.3) 38 (5.7) Infected with covid-19 after vaccination After 1st dose 121 (91.7) 11 (8.3) 0.288# After 2nd dose 15 (83.3) 3 (16.7) No 2077 (87.3) 303 (12.7) P: Pearson X2 test, #: exact probability test, *p<0.05 (significant)
- Table 5
- Multiple stepwise logistic regression for developing post-vaccination side-effects among study participants.
Factor P-value OR A 95% CI for OR Lower Upper Female 0.004* 1.50 1.10 1.90 Old age 0.007* 0.80 0.70 0.90 Non-Saudi 0.048* 2.00 1.00 4.30 University education 0.001* 2.90 2.30 3.80 Smokers 0.001* 2.60 1.70 3.90 Have chronic health problems 0.027* 1.60 1.10 2.30 Previously had positive test for COVID-19 0.001* 0.60 0.40 0.80 AstraZeneca vaccine 0.001* 2.80 1.90 4.00 ORA: adjusted odds ratio, CI: confidence interval, *p<0.05 (significant)
